tiprankstipranks
Trending News
More News >
Pfizer (PFE)
NYSE:PFE
US Market
Advertisement

Pfizer (PFE) Stock Forecast & Price Target

Compare
34,286 Followers
See the Price Targets and Ratings of:

PFE Analyst Ratings

Hold
16Ratings
Hold
4 Buy
12 Hold
0 Sell
Based on 16 analysts giving stock ratings to
Pfizer
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

PFE Stock 12 Month Forecast

Average Price Target

$28.50
▲(14.97%Upside)
Based on 16 Wall Street analysts offering 12 month price targets for Pfizer in the last 3 months. The average price target is $28.50 with a high forecast of $33.00 and a low forecast of $24.00. The average price target represents a 14.97% change from the last price of $24.79.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"22":"$22","25":"$25","28":"$28","31":"$31","34":"$34"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":33,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$33.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":28.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$28.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":24,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$24.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[22,25,28,31,34],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,24.62,25.264615384615386,25.90923076923077,26.553846153846155,27.19846153846154,27.843076923076925,28.48769230769231,29.13230769230769,29.776923076923076,30.42153846153846,31.066153846153846,31.71076923076923,32.355384615384615,{"y":33,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,24.62,24.91846153846154,25.216923076923077,25.515384615384615,25.813846153846153,26.11230769230769,26.410769230769233,26.70923076923077,27.00769230769231,27.306153846153848,27.604615384615386,27.903076923076924,28.201538461538462,{"y":28.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,24.62,24.572307692307692,24.524615384615384,24.47692307692308,24.42923076923077,24.38153846153846,24.333846153846153,24.286153846153848,24.23846153846154,24.19076923076923,24.143076923076922,24.095384615384617,24.04769230769231,{"y":24,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":26,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 31, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.64,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.11,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.79,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.25,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 32, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.5,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 39, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.18,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 29, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.58,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 31, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.5,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.67,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 44, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.08,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 45, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.06,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 55, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.62,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 37, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$33.00Average Price Target$28.50Lowest Price Target$24.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on PFE
TipRanks AITipRanks
Not Ranked
TipRanks
$28
Hold
12.95%
Upside
Reiterated
07/23/25
Pfizer's stock score is driven by strong financial performance and a robust R&D pipeline, which are counterbalanced by recent revenue declines and global trade uncertainties. The valuation is appealing due to a high dividend yield, while technical indicators suggest modest positive momentum. Overall, Pfizer is positioned for potential growth despite some challenges.
Citi
$25
Hold
0.85%
Upside
Reiterated
07/28/25
Pfizer (PFE) Gets a Hold from Citi
Bernstein Analyst forecast on PFE
Justin SmithBernstein
Bernstein
$30
Hold
21.02%
Upside
Reiterated
07/27/25
Analysts Offer Insights on Healthcare Companies: Pfizer (NYSE: PFE) and Oneview Healthcare Chess Depository Interests repr 1 (Other OTC: ONVVF)
Bank of America Securities Analyst forecast on PFE
Tim AndersonBank of America Securities
Bank of America Securities
$27
Hold
8.91%
Upside
Reiterated
07/25/25
Pfizer's Hold Rating: Navigating Competitive Pressures and Uncertain Growth Prospects
Goldman Sachs Analyst forecast on PFE
Asad HaiderGoldman Sachs
Goldman Sachs
$27
Hold
8.91%
Upside
Reiterated
07/25/25
Pfizer's Uncertain Growth Prospects and Revenue Stability Prompt Hold RatingWe highlight the following items of note: FX topline tailwind: Consistent with US pharma peers and the broader S&P500, n we expect PFE to benefit from the broad-based weakening of the dollar vs. other marjor currencies where we estimate to be a ~$190mn tailwind for 2Q25. OpEx: For the quarter, we estimate in-line R&D expenses and slightly lower SG&A n expenses. For FY25, we model to be ~ 2-3% below consensus, where our estimates of $10.9bn and $13.5bn trends towards the lower end of company guided range of $10.7- $11 .7bn and $13.3- $14.3bn range, respectively, per the company’s continued momentum and management recent commentary on cost control. Acquired IPR&D: While we do not include an IPR&D charge for 2Q25, we do n anticipate inclusion of $1 .25bn IPR&D in 3Q25 (although not yet reflected in model), per company expectation of 3SBio transaction closing.
Morgan Stanley Analyst forecast on PFE
Terence FlynnMorgan Stanley
Morgan Stanley
$32
Hold
29.08%
Upside
Reiterated
07/22/25
Hold Rating on Pfizer Due to Tafamidis Patent Expiration Risks and Revenue Decline Concerns
Wells Fargo Analyst forecast on PFE
Mohit BansalWells Fargo
Wells Fargo
$28
Hold
12.95%
Upside
Reiterated
07/08/25
Pfizer's Mixed Prospects: Hold Rating Amid Revenue Strengths and Market Challenges
J.P. Morgan Analyst forecast on PFE
Chris SchottJ.P. Morgan
J.P. Morgan
$30
Hold
21.02%
Upside
Reiterated
07/08/25
J.P. Morgan Sticks to Their Hold Rating for Pfizer (PFE)
Guggenheim Analyst forecast on PFE
Vamil DivanGuggenheim
Guggenheim
$33
Buy
33.12%
Upside
Reiterated
06/17/25
Analysts Offer Insights on Healthcare Companies: Pfizer (NYSE: PFE) and Sagimet Biosciences, Inc. Class A (NASDAQ: SGMT)
UBS
$25
Hold
0.85%
Upside
Reiterated
06/12/25
Analysts Conflicted on These Healthcare Names: Pfizer (NYSE: PFE) and Chemomab Therapeutics (NASDAQ: CMMB)
BMO Capital Analyst forecast on PFE
Evan SeigermanBMO Capital
BMO Capital
$30
Buy
21.02%
Upside
Reiterated
06/12/25
Pfizer's Strategic Positioning in Breast Cancer Market and Growth Potential
Cantor Fitzgerald Analyst forecast on PFE
Carter GouldCantor Fitzgerald
Cantor Fitzgerald
$24
Hold
-3.19%
Downside
Reiterated
06/10/25
Cantor Fitzgerald Remains a Hold on Pfizer (PFE)
Jefferies Analyst forecast on PFE
Akash TewariJefferies
Jefferies
$33
Buy
33.12%
Upside
Reiterated
06/04/25
Jefferies Sticks to Their Buy Rating for Pfizer (PFE)
Leerink Partners Analyst forecast on PFE
David RisingerLeerink Partners
Leerink Partners
Hold
Reiterated
06/02/25
Analysts Conflicted on These Healthcare Names: Pfizer (NYSE: PFE), Sagimet Biosciences, Inc. Class A (NASDAQ: SGMT) and Janux Therapeutics Inc (NASDAQ: JANX)
DBS
$30
Buy
21.02%
Upside
Reiterated
05/30/25
Pfizer's Strong Financial Performance and Promising Pipeline Drive Buy Rating
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on PFE
TipRanks AITipRanks
Not Ranked
TipRanks
$28
Hold
12.95%
Upside
Reiterated
07/23/25
Pfizer's stock score is driven by strong financial performance and a robust R&D pipeline, which are counterbalanced by recent revenue declines and global trade uncertainties. The valuation is appealing due to a high dividend yield, while technical indicators suggest modest positive momentum. Overall, Pfizer is positioned for potential growth despite some challenges.
Citi
$25
Hold
0.85%
Upside
Reiterated
07/28/25
Pfizer (PFE) Gets a Hold from Citi
Bernstein Analyst forecast on PFE
Justin SmithBernstein
Bernstein
$30
Hold
21.02%
Upside
Reiterated
07/27/25
Analysts Offer Insights on Healthcare Companies: Pfizer (NYSE: PFE) and Oneview Healthcare Chess Depository Interests repr 1 (Other OTC: ONVVF)
Bank of America Securities Analyst forecast on PFE
Tim AndersonBank of America Securities
Bank of America Securities
$27
Hold
8.91%
Upside
Reiterated
07/25/25
Pfizer's Hold Rating: Navigating Competitive Pressures and Uncertain Growth Prospects
Goldman Sachs Analyst forecast on PFE
Asad HaiderGoldman Sachs
Goldman Sachs
$27
Hold
8.91%
Upside
Reiterated
07/25/25
Pfizer's Uncertain Growth Prospects and Revenue Stability Prompt Hold RatingWe highlight the following items of note: FX topline tailwind: Consistent with US pharma peers and the broader S&P500, n we expect PFE to benefit from the broad-based weakening of the dollar vs. other marjor currencies where we estimate to be a ~$190mn tailwind for 2Q25. OpEx: For the quarter, we estimate in-line R&D expenses and slightly lower SG&A n expenses. For FY25, we model to be ~ 2-3% below consensus, where our estimates of $10.9bn and $13.5bn trends towards the lower end of company guided range of $10.7- $11 .7bn and $13.3- $14.3bn range, respectively, per the company’s continued momentum and management recent commentary on cost control. Acquired IPR&D: While we do not include an IPR&D charge for 2Q25, we do n anticipate inclusion of $1 .25bn IPR&D in 3Q25 (although not yet reflected in model), per company expectation of 3SBio transaction closing.
Morgan Stanley Analyst forecast on PFE
Terence FlynnMorgan Stanley
Morgan Stanley
$32
Hold
29.08%
Upside
Reiterated
07/22/25
Hold Rating on Pfizer Due to Tafamidis Patent Expiration Risks and Revenue Decline Concerns
Wells Fargo Analyst forecast on PFE
Mohit BansalWells Fargo
Wells Fargo
$28
Hold
12.95%
Upside
Reiterated
07/08/25
Pfizer's Mixed Prospects: Hold Rating Amid Revenue Strengths and Market Challenges
J.P. Morgan Analyst forecast on PFE
Chris SchottJ.P. Morgan
J.P. Morgan
$30
Hold
21.02%
Upside
Reiterated
07/08/25
J.P. Morgan Sticks to Their Hold Rating for Pfizer (PFE)
Guggenheim Analyst forecast on PFE
Vamil DivanGuggenheim
Guggenheim
$33
Buy
33.12%
Upside
Reiterated
06/17/25
Analysts Offer Insights on Healthcare Companies: Pfizer (NYSE: PFE) and Sagimet Biosciences, Inc. Class A (NASDAQ: SGMT)
UBS
$25
Hold
0.85%
Upside
Reiterated
06/12/25
Analysts Conflicted on These Healthcare Names: Pfizer (NYSE: PFE) and Chemomab Therapeutics (NASDAQ: CMMB)
BMO Capital Analyst forecast on PFE
Evan SeigermanBMO Capital
BMO Capital
$30
Buy
21.02%
Upside
Reiterated
06/12/25
Pfizer's Strategic Positioning in Breast Cancer Market and Growth Potential
Cantor Fitzgerald Analyst forecast on PFE
Carter GouldCantor Fitzgerald
Cantor Fitzgerald
$24
Hold
-3.19%
Downside
Reiterated
06/10/25
Cantor Fitzgerald Remains a Hold on Pfizer (PFE)
Jefferies Analyst forecast on PFE
Akash TewariJefferies
Jefferies
$33
Buy
33.12%
Upside
Reiterated
06/04/25
Jefferies Sticks to Their Buy Rating for Pfizer (PFE)
Leerink Partners Analyst forecast on PFE
David RisingerLeerink Partners
Leerink Partners
Hold
Reiterated
06/02/25
Analysts Conflicted on These Healthcare Names: Pfizer (NYSE: PFE), Sagimet Biosciences, Inc. Class A (NASDAQ: SGMT) and Janux Therapeutics Inc (NASDAQ: JANX)
DBS
$30
Buy
21.02%
Upside
Reiterated
05/30/25
Pfizer's Strong Financial Performance and Promising Pipeline Drive Buy Rating
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Pfizer

1 Month
xxx
Success Rate
19/35 ratings generated profit
54%
Average Return
+0.93%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 54.29% of your transactions generating a profit, with an average return of +0.93% per trade.
3 Months
xxx
Success Rate
24/35 ratings generated profit
69%
Average Return
+2.71%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 68.57% of your transactions generating a profit, with an average return of +2.71% per trade.
1 Year
Vamil DivanGuggenheim
Success Rate
26/35 ratings generated profit
74%
Average Return
+5.17%
reiterated a buy rating last month
Copying Vamil Divan's trades and holding each position for 1 Year would result in 74.29% of your transactions generating a profit, with an average return of +5.17% per trade.
2 Years
xxx
Success Rate
26/35 ratings generated profit
74%
Average Return
+7.85%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 74.29% of your transactions generating a profit, with an average return of +7.85% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

PFE Analyst Recommendation Trends

Rating
Mar 25
Apr 25
May 25
Jun 25
Jul 25
Strong Buy
0
2
2
2
0
Buy
13
14
12
15
10
Hold
26
44
45
55
37
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
39
60
59
72
47
In the current month, PFE has received 10 Buy Ratings, 37 Hold Ratings, and 0 Sell Ratings. PFE average Analyst price target in the past 3 months is 28.50.
Each month's total comprises the sum of three months' worth of ratings.

PFE Financial Forecast

PFE Earnings Forecast

Next quarter’s earnings estimate for PFE is $0.58 with a range of $0.53 to $0.62. The previous quarter’s EPS was $0.92. PFE beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.91% of the time in the same period. In the last calendar year PFE has Outperformed its overall industry.
Next quarter’s earnings estimate for PFE is $0.58 with a range of $0.53 to $0.62. The previous quarter’s EPS was $0.92. PFE beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.91% of the time in the same period. In the last calendar year PFE has Outperformed its overall industry.

PFE Sales Forecast

Next quarter’s sales forecast for PFE is $13.56B with a range of $13.23B to $14.16B. The previous quarter’s sales results were $13.71B. PFE beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 47.40% of the time in the same period. In the last calendar year PFE has Outperformed its overall industry.
Next quarter’s sales forecast for PFE is $13.56B with a range of $13.23B to $14.16B. The previous quarter’s sales results were $13.71B. PFE beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 47.40% of the time in the same period. In the last calendar year PFE has Outperformed its overall industry.

PFE Stock Forecast FAQ

What is PFE’s average 12-month price target, according to analysts?
Based on analyst ratings, Pfizer’s 12-month average price target is 28.50.
    What is PFE’s upside potential, based on the analysts’ average price target?
    Pfizer has 14.97% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is PFE a Buy, Sell or Hold?
          Pfizer has a consensus rating of Hold which is based on 4 buy ratings, 12 hold ratings and 0 sell ratings.
            What is Pfizer’s price target?
            The average price target for Pfizer is 28.50. This is based on 16 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $33.00 ,the lowest forecast is $24.00. The average price target represents 14.97% Increase from the current price of $24.79.
              What do analysts say about Pfizer?
              Pfizer’s analyst rating consensus is a Hold. This is based on the ratings of 16 Wall Streets Analysts.
                How can I buy shares of PFE?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis